New symptomatic strategies in Alzheimer's disease

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 1, 2004, Pages 13-19

  Johnson, Christopher N ^a   Roland, Alexander ^a   Upton, Neil ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 AMINOPROPYLBUTYLPHOSPHINIC ACID; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 4 AMINO N [2,6 BIS(METHYLAMINO) 4 PYRIMIDINYL]BENZENESULFONAMIDE; 5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ACETYLCHOLINE; ATROPINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; DOPAMINE; GALANTAMINE; GLUTAMIC ACID; ISPRONICLINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERVE CELL ADHESION MOLECULE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NORADRENALIN; RIVASTIGMINE; SEROTONIN 6 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR AFFECTING AGENT; SL 650155; TACRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANOREXIA; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COST BENEFIT ANALYSIS; DIARRHEA; DRUG APPROVAL; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HUMAN; LIVER TOXICITY; NAUSEA; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; REVIEW; STRUCTURE ANALYSIS; SYMPTOMATOLOGY; UNITED STATES; VOMITING;

EID: 13444278941     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.08.003     Document Type: Review

References (26)

1. P.N. Tariot H.J. Federoff Current treatment for Alzheimer's disease and future prospects Alzheimer Dis. Assoc. Disord. 17 2003 S105-S113
2. A.V. Terry Jr J.J. Buccafusco The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development J. Pharmacol. Exp. Ther. 306 2003 821-827
3. L.S. Schneider P.N. Tariot Cognitive enhancers and treatments for Alzheimer's disease (A. Tasman J. Kay J.A. Lieberman eds.) In Psychiatry (2nd edn) 2003 John Wiley and Sons London 2096-2111
4. Birks, J.S. and Harvey, R. (2003) Donepezil for dementia due to Alzheimer's disease (Cochrane Review). In The Cochrane Database of Systematic Reviews Issue 1, Oxford: Update Software http://www.update-software.com/cochrane/
5. J. Birks et al. Rivastigmine for Alzheimer's disease (Cochrane Review) The Cochrane Database of Systematic Reviews Issue 1 2003 Update Software Oxford
6. J. Olin L. Schneider Galantamine for Alzheimer's disease (Cochrane Review) The Cochrane Database of Systematic Reviews Issue 1 2003 Update Software Oxford
7. R.S. Doody et al. Practice parameter: Management of dementia (an evidence-based review) Neurology 56 2001 1154-1166
8. AD2000 Collaborative Group (2004) Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. Lancet 363, 2105-2115
9. W. Danysz C.G. Parsons The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence Int. J. Geriatr. Psychiatry 18 2003 S23-S32
10. M.R. Farlow et al. Memantine/donepezil dual therapy is superior to placebo/donepezil therapy for treatment of moderate to severe AD Neurology 60 Suppl. 1 2003 A412
11. A. Areosa Sastre F. Sherriff Memantine for dementia (Cochrane Review) In The Cochrane Database of Systematic Reviews Issue 1 2003 Update Software Oxford
12. M. Bourin et al. Nicotinic receptors and Alzheimer's disease Curr. Med. Res. Opin. 19 2003 169-177
13. A. Potter et al. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease Psychopharmacology (Berlin) 142 1999 334-342
14. W.R. Kem The brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: Studies with DMXBA (GTS-21) Behav. Brain Res. 113 2000 169-181
15. 6 receptor antagonists Curr. Opin. Invest. Drugs 2 2001 104-109
16. 7 J. Med. Chem. 46 2003 2795-2812
17. 6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus Neuropsychopharmacology 25 2001 662-668
18. 6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex Synapse 51 2003 158-164
19. R. Gerlai Behavioral tests of hippocampal function: Simple paradigms complex problems Behav. Brain Res. 125 2001 269-277
20. 6 receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats Neuropsychopharmacology 29 2004 93-100
21. 6 receptor antagonists SB-271046 and SB-399885 increase basal and learning induced NCAM-polysialylation in the rat dentate gyrus. Society for Neuroscience 33rd Annual Meeting, New Orleans, USA (Abstract no. 835.21) http://sfn.scholarone.com/itin2003/index.html
22. 4 receptor partial agonist with potent cognition enhancing properties. Society for Neuroscience 32nd Annual Meeting, Orlando, USA (Abstract no. 786.16) http://sfn.scholarone.com/itin2002/index.html
23. W. Danysz CX-516 Cortex Pharmaceuticals Curr. Opin. Invest. Drugs 3 2002 1081-1088
24. 3 receptor (H3R) antagonist. Society for Neuroscience 33rd Annual Meeting, New Orleans, USA (Abstract no. 296.20) http://sfn.scholarone.com/itin2003/index.html
25. 1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease. Implications in future therapy J. Mol. Neurosci. 20 2003 349-356
26. 6) receptor antagonists in rodent models of learning J. Pharmacol. Exp. Ther. 307 2003 682-691